髋骨关节炎需全髋关节置换术患者接受关节腔内皮质类固醇注射的满意度有限且风险增加
研究调查510例全髋关节置换术前接受关节腔内皮质类固醇注射的髋骨关节炎患者,104例(129髋)回应,平均疼痛缓解6.2周,16.5%不满意,44.4%不愿再次注射;回顾性分析1090例全髋关节置换术患者,247例(22.7%)术前接受注射,与感染性翻修率升高相关(2.0% vs 0.5%,比值比=4.98,P=0.014)。
要点
- 术前皮质类固醇注射平均疼痛缓解6.2周,16.5%患者不满意,44.4%不愿再次注射。
- 全髋关节置换术前接受皮质类固醇注射与感染性翻修率升高相关(2.0% vs 0.5%,比值比=4.98,P=0.014)。
- 无菌性翻修率两组无显著差异(P=0.28)。
核心结论
- 近半数全髋关节置换术前接受皮质类固醇注射的患者不愿再次注射,平均疼痛缓解约6周;术前注射与感染性翻修风险增加相关,进一步引发对全髋关节置换术前皮质类固醇注射价值的担忧。
研究设计与样本
- 对510例全髋关节置换术前至少接受一次皮质类固醇注射的患者发放问卷,104例(129髋)回应,回应率20.4%。
- 对本机构1090例全髋关节置换术患者进行回顾性审查,评估皮质类固醇注射与术后潜在并发症的关联。
- 采用卡方检验、Fisher精确检验和逻辑回归进行组间比较。
主要发现
- 问卷回应者报告视觉模拟评分疼痛平均降低5.2(标准差=3.2),平均缓解持续6.2周(标准差=8.4)。
- 45.8%的患者每髋注射一次,平均每髋注射2.2次(范围1至10次)。
- 16.5%报告对皮质类固醇注射不满意,44.4%表示不会再次接受皮质类固醇注射。
- 1090例全髋关节置换术患者中,247例(22.7%)术前接受皮质类固醇注射,与感染性翻修率升高相关(2.0% vs 0.5%,比值比=4.98,P=0.014)。
- 无菌性翻修率无显著差异(P=0.28)。
局限性
- 问卷回应率为20.4%。
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The value of intra-articular corticosteroid injections (CSI) in the treatment of hip osteoarthritis has come into question due to concerns regarding efficacy and complication profile. This study aimed to assess patient satisfaction after CSI for hip osteoarthritis and the association of CSI with potential complications following subsequent total hip arthroplasty (THA). METHODS: A survey was sent to 510 patients who received at least one CSI before THA. Data collected included reduction in visual analog scale pain scores, duration of relief, and patient satisfaction. A retrospective review of 1,090 THA patients at our institution was performed to evaluate the association of CSI to potential complications following THA. Chi-square, Fisher exact, and logistic regression were used for comparison between groups. A total of 104 patients, who had injections in 129 hips, responded (response rate 20.4%); there was 45.8% of patients who had one injection per hip, with a mean of 2.2 injections per hip (range, one to 10). RESULTS: Patients reported a mean reduction in visual analog scale pain scores of 5.2 (SD = 3.2), with the average relief lasting 6.2 weeks (SD = 8.4). Of note, 16.5% reported no satisfaction after CSI, and 44.4% stated they would not undergo CSI again. Of the 1,090 THA patients that were retrospectively reviewed, 247 patients (22.7%) received a CSI before THA; this was associated with an increased rate of septic revision (2.0 versus 0.5%, odds ratio = 4.98, P = 0.014). There were no significant differences in aseptic revision rates (P = 0.28). CONCLUSIONS: Almost half of the patients who received a CSI before THA would not do so again, with average pain relief lasting approximately 6 weeks. Given the increased risk of septic revision for those who underwent CSI before THA, this draws further concern regarding the value of CSI before THA.
引用
- Metz AK, Rainey JP, Blackburn BE, et al. Limited Satisfaction and Increased Risk With Intra-articular Corticosteroid Injections in Patients Who Have Hip Osteoarthritis Needing Total Hip Arthroplasty. J Arthroplasty. 2025. PMID: 40113183. doi:10.1016/j.arth.2025.03.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。